Protalix BioTherapeutics Inc (PLX)
1.265
+0.02
(+1.20%)
USD |
NYAM |
Nov 04, 16:00
1.26
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Revenue (Quarterly): 13.47M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 13.47M |
| March 31, 2024 | 3.748M |
| December 31, 2023 | 10.49M |
| September 30, 2023 | 10.34M |
| June 30, 2023 | 35.08M |
| March 31, 2023 | 9.588M |
| December 31, 2022 | 8.617M |
| September 30, 2022 | 14.18M |
| June 30, 2022 | 8.753M |
| March 31, 2022 | 16.08M |
| December 31, 2021 | 8.549M |
| September 30, 2021 | 12.05M |
| June 30, 2021 | 6.427M |
| March 31, 2021 | 11.32M |
| December 31, 2020 | 19.50M |
| September 30, 2020 | 10.79M |
| June 30, 2020 | 10.97M |
| March 31, 2020 | 21.65M |
| December 31, 2019 | 17.76M |
| September 30, 2019 | 14.25M |
| June 30, 2019 | 12.25M |
| March 31, 2019 | 10.44M |
| December 31, 2018 | 10.35M |
| September 30, 2018 | 12.34M |
| June 30, 2018 | 4.838M |
| Date | Value |
|---|---|
| March 31, 2018 | 6.714M |
| December 31, 2017 | 4.305M |
| September 30, 2017 | 7.526M |
| June 30, 2017 | 6.358M |
| March 31, 2017 | 2.889M |
| December 31, 2016 | 2.081M |
| September 30, 2016 | 4.67M |
| June 30, 2016 | 1.769M |
| March 31, 2016 | 0.679M |
| December 31, 2015 | |
| September 30, 2015 | 1.336M |
| June 30, 2015 | 1.336M |
| March 31, 2015 | 1.692M |
| December 31, 2014 | -10.25M |
| September 30, 2014 | 3.707M |
| June 30, 2014 | 2.686M |
| March 31, 2014 | 7.383M |
| December 31, 2013 | -10.39M |
| September 30, 2013 | 3.359M |
| June 30, 2013 | 3.064M |
| March 31, 2013 | 3.968M |
| December 31, 2012 | 0.048M |
| September 30, 2012 | 5.39M |
| June 30, 2012 | 25.26M |
| March 31, 2012 | 3.728M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.748M
Minimum
Mar 2024
35.08M
Maximum
Jun 2023
13.12M
Average
10.97M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
| Aethlon Medical Inc | -- |
| Predictive Oncology Inc | 0.2787M |
| bluebird bio Inc | 16.10M |
| AIM ImmunoTech Inc | 0.05M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.203M |
| Total Expenses (Quarterly) | 15.90M |
| EPS Diluted (Quarterly) | -0.03 |
| Enterprise Value | 67.32M |
| Gross Profit Margin (Quarterly) | 29.82% |
| Profit Margin (Quarterly) | -16.35% |
| Earnings Yield | -18.18% |
| Normalized Earnings Yield | -18.18 |